Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2627)	10/12/2009 11:29:11 AM
From: Jibacoa	Respond to of 3722

RPTPD opened with a small UG and is still up 22.36% on volume of > 249,000 still below its ADV bigcharts.marketwatch.com It announced positive findings from its open label PIIa of delayed-release cysteamine bitartrate in adolescent patients with non-alcoholic steatohepatitis,which is believed to affect 2% to 5% of the U.S. population. At the completion of the six-month phase, the study achieved the primary endpoint: mean blood levbels of ALT, a common biomarker for NASH, were reduced by over 50%. Additionally, over half of the study participants had achieved normalized ALT levels by the end of the treatment phase. The stock traded as H as $11.73 on the spike of Aug 26 The volume that day was 777,500 In spite of the lower revenues, RPTD has been trimming its loss on a sequential basis in the last 4Qs. It still trades around 0.85xBV and the insiders reportedly hold >40% Back in May they had announced plans to liquidate the asstes and dissolve the company. I don't know if they have any change on those plans.<g> The stock traded above the 3000 level back in 2000 <g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2627)	1/13/2010 11:28:51 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MRNA was up 97% at its intraday H at 9:40AM and is still up 60.17% after some positive news at its presentation in Frisco.<g> The stock opened with a good UG, which it seems isn't going to close today.<g> bigcharts.marketwatch.com MRNA reported a reduction in tumor growth in both liver and bladder cancers by targeting genes key to tumor progression, via both systemic and local delivery with the Company's proprietary UsiRNAs delivered by its novel DiLA2 platform. In addition, MDRNA disclosed the establishment of an early collaborative effort with a major international pharmaceutical company, its second such effort. finance.yahoo.com Bernard